Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.

Zhang D, Zhou Y, Ma Y, Jiang P, Lv H, Liu S, Mu Y, Zhou C, Xiao S, Ji G, Liu P, Zhang N, Sun D, Sun H, Wu N, Jin Y

Open source

DOI
10.1038/s41420-022-01153-8
Published
2022 Aug 17
Container
Cell death discovery
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41420-022-01153-8,
  title = {Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.},
  author = {Zhang D and Zhou Y and Ma Y and Jiang P and Lv H and Liu S and Mu Y and Zhou C and Xiao S and Ji G and Liu P and Zhang N and Sun D and Sun H and Wu N and Jin Y},
  year = {2022},
  journal = {Cell death discovery},
  doi = {10.1038/s41420-022-01153-8},
  url = {https://doi.org/10.1038/s41420-022-01153-8}
}

RIS

TY  - JOUR
TI  - Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.
AU  - Zhang D
AU  - Zhou Y
AU  - Ma Y
AU  - Jiang P
AU  - Lv H
AU  - Liu S
AU  - Mu Y
AU  - Zhou C
AU  - Xiao S
AU  - Ji G
AU  - Liu P
AU  - Zhang N
AU  - Sun D
AU  - Sun H
AU  - Wu N
AU  - Jin Y
PY  - 2022
JO  - Cell death discovery
DO  - 10.1038/s41420-022-01153-8
UR  - https://doi.org/10.1038/s41420-022-01153-8
ER  - 

APA

D, Z., Y, Z., Y, M., P, J., H, L., S, L., Y, M., C, Z., S, X., G, J., P, L., N, Z., D, S., H, S., N, W., & Y, J. (2022). Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.. Cell death discovery. https://doi.org/10.1038/s41420-022-01153-8

Source records